Phase I study of SON-1210
Latest Information Update: 11 Feb 2022
At a glance
- Drugs SON 1210 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 08 Feb 2022 According to a Sonnet BioTherapeutics Holdings media release, this study is expected to begin in the first half of 2022.
- 17 Oct 2019 New trial record